Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. - Tan-Chiu,E..; Yothers,G..; Romond,E..; Geyer,C.E.; Ewer,M..; Keefe,D..; et,al.. (J Clin Oncol, 2005)